Supplemental Digital Content 6: Non-ocular Serious Adverse Events, Regardless of Study Drug Relationship, over 12 months (Safety set*)

Preferred term, n (%)	Ranibizumab 0.5 mg		vPDT	
	Group I (VA stabilization) (n = 182)	Group II (disease activity) (n = 185)	Group III (with ranibizumab 0.5 mg from Month 3) (n = 75)	Group III (without ranibizumab 0.5 mg from Month 3) (n = 14)
Non-ocular SAEs, total	6 (3.3)	13 (7.0)	6 (8.0)	0
Atrial fibrillation	1 (0.5)	0	0	0
Hemorrhoids	1 (0.5)	1 (0.5)	0	0
Varices esophageal	1 (0.5)	0	0	0
Concussion	1 (0.5)	0	0	0
Joint dislocation	1 (0.5)	0	0	0
Gastrointestinal stromal tumor	1 (0.5)	0	0	0
Transient ischemic attack	1 (0.5)	0	0	0
Henoch-Schonlein purpura	1 (0.5)	0	0	0

Coronary artery disease	0	1 (0.5)	1 (1.3)	0
Supraventricular tachycardia	0	2 (1.1)	0	0
Inguinal hernia	0	2 (1.1)	0	0
Intestinal obstruction	0	1 (0.5)	0	0
Hepatic steatosis	0	1 (0.5)	0	0
Anal abscess	0	1 (0.5)	0	0
Cellulitis	0	1 (0.5)	0	0
Pharyngitis bacterial	0	1 (0.5)	0	0
Pneumonia	0	1 (0.5)	0	0
Radius fracture	0	1 (0.5)	0	0
Osteoporotic fracture	0	1 (0.5)	0	0
Bladder hyperemia	0	1 (0.5)	0	0
Arrhythmia	0	0	1 (1.3)	0
Rectal polyp	0	0	1 (1.3)	0
Appendicitis	0	0	1 (1.3)	0

Physical examination abnormal	0	0	1 (1.3)	0
Shock hypoglycemic	0	0	1 (1.3)	0
Type 2 diabetes mellitus	0	0	1 (1.3)	0
Rhabdomyolysis	0	0	1 (1.3)	0
Oligoastrocytoma	0	0	1 (1.3)	0
Syncope	0	0	1 (1.3)	0

*Consisted of all patients who received at least one application of study treatment and had at least one post-baseline safety assessment.

A patient with multiple occurrences of an AE under one treatment is counted only once in the AE category.

Preferred terms are sorted in descending frequency, as reported in the Ranibizumab 0.5 mg (Group I) column.

AE, adverse event; SAE, serious adverse event; vPDT, verteporfin photodynamic therapy